Miramar, Florida, February 16, 2011 - MIRAMAR, Fla. - Altor BioScience Corporation (Altor) announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant by the National Institute of Allergy and Infectious Diseases.

The award of $237,181 for the project entitled “Evaluating Relevant Vaccine Epitopes Displayed on HIV-Infected Cells” will provide Altor the necessary resources to create over 20 single chain T cell receptor (scTCR) proteins based on its proprietary STARTM technology. This portfolio of novel reagents will serve as a valuable tool in better understanding the time course of HIV infection and the expression of various HIV proteins, as seen by the display of epitopes from these proteins on the surfaces of HIV-infected cells. This information should play a major role in rational vaccine design against HIV.

Hing Wong, Ph.D., Altor's CEO commented, "Altor is extremely pleased to receive this SBIR award from NIH/NIAID and its recognition of the potential of our proprietary STAR™ in vaccine design against viral infections. We are particularly delighted to be a part of a worldwide effort on HIV vaccine development. This also helps us to diversify our product pipeline from cancer and inflammatory disease into infectious disease treatments and prevention.”

About Altor’s STAR™ Technology

Antigen-specific T-cell receptor (TCR) molecules on T lymphocytes bind peptide antigens presented in the context of MHCs on tumor or virus-infected cells and is the basis for their use as targeting agents for cancer and viral therapeutics. Altor has captured this potential with the development of its proprietary STAR™ (Soluble T-cell Antigen Receptor) technology for producing biologically active, soluble TCR molecules in a single-chain format. These scTCRs can be fused to bioactive proteins that retain the ability of the TCR to specifically recognize novel targets on virus-infected or cancerous cells, including intracellular antigens that are not accessible to therapeutic antibodies. Altor has developed STAR™ fusions with cytokines and antibody-like fusions which function as therapeutics. STAR™ fusions are ideally suited to deliver anti-cancer and anti-viral drugs, such as approved immunomodulatory cytokines, cytotoxic drugs, radioisotopes, and imaging agents, directly to diseased cells and tissues.

About Altor BioScience

Altor is a privately held biotechnology company developing targeted immunotherapies for treating cancer, viral infections, and inflammatory diseases based on its proprietary, integrated technologies for creating soluble TCRs. Altor currently has three product candidates at mid and late phases of clinical development. Visit www.altorbioscience.com for details.

Contact: Altor Bioscience Corporation, Peter Rhode, Ph.D., 954-443-8600